Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: We recently discovered a sudden and sustained 3-fold increase in the pharmacy expenditures for quetiapine fumarate, an atypical antipsychotic agent, at the Minneapolis Veterans Affairs Medical Center (VAMC). This occurred in April 2000, which was 28 months after the drug became available in the United States and 5 months after it was placed on the hospital formulary. We investigated this sudden and dramatic increase in prescription costs for this drug at our institution.
Dieperink ME, Drogemuller L. Industry-Sponsored Grand Rounds and Prescribing Behavior. JAMA. 2001;285(11):1443-1444. doi:10.1001/jama.285.11.1443